Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study

Shu Chuan Chang, Chin Tun Hung, Shu Fen Li, Horng Mo Lee, Yueh Chin Chung, Lee Wen Pai, Sheng Shun Yang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Purpose: Interferon (IFN) is able to induce significant psychiatric side effects in chronic hepatitis C (CHC) patients, whereas the risk of nonpsychotic mental disorder (NPMD) development in antiviral-treated mentally healthy CHC patients remains obscure. We used a population-based study to assess the risk of NPMD development in patients who had undergone antiviral treatment compared with untreated chronic hepatitis C virus (HCV)-infected and nonalcoholic fatty liver disease (NAFLD) patients. Methods: Data were retrieved from Taiwan's National Health Insurance Research Database cohort consisting of 1 million individuals for a longitudinal analysis. A total of 313 mentally healthy CHC patients who received IFN-based antiviral therapy were recruited and compared with those without antiviral therapy and NAFLD patients. The Chi-square test was used to obtain the hazard ratio and 95% confidence interval. Results: Among the 313 CHC patients receiving pegylated interferon/ribavirin therapy, 62 patients (19.8%) were associated with NPMD. In the comparison cohort, composed of 313 age- and sex-matched CHC patients not receiving antiviral therapy, 70 patients (22.4%) were associated with NPMD. The Chi-square analysis revealed that antiviral therapy was not significantly associated with NPMD. The diagnosis of HCV-infected hepatitis was independently associated with NPMD when compared with NAFLD. The hazard ratio was 1.67 (95% confidence interval, 1.11-2.52; p = 0.018). Furthermore, generalized anxiety disorder was specifically higher in HCV-infected patients than those with NAFLD. Conclusion: Patients with HCV infection are at high risk of developing NPMD with or without IFN-based therapy.

Original languageEnglish
Pages (from-to)829-834
Number of pages6
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume114
Issue number9
DOIs
Publication statusPublished - Sep 1 2015
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Mental Disorders
Antiviral Agents
Population
Hepacivirus
Interferons
Therapeutics
Confidence Intervals
Ribavirin
National Health Programs
Virus Diseases
Chi-Square Distribution
Anxiety Disorders
Taiwan
Hepatitis
Psychiatry
Databases

Keywords

  • Antiviral therapy
  • Chronic hepatitis C
  • Nonalcoholic fatty liver disease
  • Nonpsychotic mental disorders
  • Population-based study

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients : A population-based study. / Chang, Shu Chuan; Hung, Chin Tun; Li, Shu Fen; Lee, Horng Mo; Chung, Yueh Chin; Pai, Lee Wen; Yang, Sheng Shun.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 114, No. 9, 01.09.2015, p. 829-834.

Research output: Contribution to journalArticle

Chang, Shu Chuan ; Hung, Chin Tun ; Li, Shu Fen ; Lee, Horng Mo ; Chung, Yueh Chin ; Pai, Lee Wen ; Yang, Sheng Shun. / Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients : A population-based study. In: Journal of the Formosan Medical Association = Taiwan yi zhi. 2015 ; Vol. 114, No. 9. pp. 829-834.
@article{5262ef97494a4566a81e7a0cddbc3be1,
title = "Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study",
abstract = "Background/Purpose: Interferon (IFN) is able to induce significant psychiatric side effects in chronic hepatitis C (CHC) patients, whereas the risk of nonpsychotic mental disorder (NPMD) development in antiviral-treated mentally healthy CHC patients remains obscure. We used a population-based study to assess the risk of NPMD development in patients who had undergone antiviral treatment compared with untreated chronic hepatitis C virus (HCV)-infected and nonalcoholic fatty liver disease (NAFLD) patients. Methods: Data were retrieved from Taiwan's National Health Insurance Research Database cohort consisting of 1 million individuals for a longitudinal analysis. A total of 313 mentally healthy CHC patients who received IFN-based antiviral therapy were recruited and compared with those without antiviral therapy and NAFLD patients. The Chi-square test was used to obtain the hazard ratio and 95{\%} confidence interval. Results: Among the 313 CHC patients receiving pegylated interferon/ribavirin therapy, 62 patients (19.8{\%}) were associated with NPMD. In the comparison cohort, composed of 313 age- and sex-matched CHC patients not receiving antiviral therapy, 70 patients (22.4{\%}) were associated with NPMD. The Chi-square analysis revealed that antiviral therapy was not significantly associated with NPMD. The diagnosis of HCV-infected hepatitis was independently associated with NPMD when compared with NAFLD. The hazard ratio was 1.67 (95{\%} confidence interval, 1.11-2.52; p = 0.018). Furthermore, generalized anxiety disorder was specifically higher in HCV-infected patients than those with NAFLD. Conclusion: Patients with HCV infection are at high risk of developing NPMD with or without IFN-based therapy.",
keywords = "Antiviral therapy, Chronic hepatitis C, Nonalcoholic fatty liver disease, Nonpsychotic mental disorders, Population-based study",
author = "Chang, {Shu Chuan} and Hung, {Chin Tun} and Li, {Shu Fen} and Lee, {Horng Mo} and Chung, {Yueh Chin} and Pai, {Lee Wen} and Yang, {Sheng Shun}",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.jfma.2013.08.011",
language = "English",
volume = "114",
pages = "829--834",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients

T2 - A population-based study

AU - Chang, Shu Chuan

AU - Hung, Chin Tun

AU - Li, Shu Fen

AU - Lee, Horng Mo

AU - Chung, Yueh Chin

AU - Pai, Lee Wen

AU - Yang, Sheng Shun

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background/Purpose: Interferon (IFN) is able to induce significant psychiatric side effects in chronic hepatitis C (CHC) patients, whereas the risk of nonpsychotic mental disorder (NPMD) development in antiviral-treated mentally healthy CHC patients remains obscure. We used a population-based study to assess the risk of NPMD development in patients who had undergone antiviral treatment compared with untreated chronic hepatitis C virus (HCV)-infected and nonalcoholic fatty liver disease (NAFLD) patients. Methods: Data were retrieved from Taiwan's National Health Insurance Research Database cohort consisting of 1 million individuals for a longitudinal analysis. A total of 313 mentally healthy CHC patients who received IFN-based antiviral therapy were recruited and compared with those without antiviral therapy and NAFLD patients. The Chi-square test was used to obtain the hazard ratio and 95% confidence interval. Results: Among the 313 CHC patients receiving pegylated interferon/ribavirin therapy, 62 patients (19.8%) were associated with NPMD. In the comparison cohort, composed of 313 age- and sex-matched CHC patients not receiving antiviral therapy, 70 patients (22.4%) were associated with NPMD. The Chi-square analysis revealed that antiviral therapy was not significantly associated with NPMD. The diagnosis of HCV-infected hepatitis was independently associated with NPMD when compared with NAFLD. The hazard ratio was 1.67 (95% confidence interval, 1.11-2.52; p = 0.018). Furthermore, generalized anxiety disorder was specifically higher in HCV-infected patients than those with NAFLD. Conclusion: Patients with HCV infection are at high risk of developing NPMD with or without IFN-based therapy.

AB - Background/Purpose: Interferon (IFN) is able to induce significant psychiatric side effects in chronic hepatitis C (CHC) patients, whereas the risk of nonpsychotic mental disorder (NPMD) development in antiviral-treated mentally healthy CHC patients remains obscure. We used a population-based study to assess the risk of NPMD development in patients who had undergone antiviral treatment compared with untreated chronic hepatitis C virus (HCV)-infected and nonalcoholic fatty liver disease (NAFLD) patients. Methods: Data were retrieved from Taiwan's National Health Insurance Research Database cohort consisting of 1 million individuals for a longitudinal analysis. A total of 313 mentally healthy CHC patients who received IFN-based antiviral therapy were recruited and compared with those without antiviral therapy and NAFLD patients. The Chi-square test was used to obtain the hazard ratio and 95% confidence interval. Results: Among the 313 CHC patients receiving pegylated interferon/ribavirin therapy, 62 patients (19.8%) were associated with NPMD. In the comparison cohort, composed of 313 age- and sex-matched CHC patients not receiving antiviral therapy, 70 patients (22.4%) were associated with NPMD. The Chi-square analysis revealed that antiviral therapy was not significantly associated with NPMD. The diagnosis of HCV-infected hepatitis was independently associated with NPMD when compared with NAFLD. The hazard ratio was 1.67 (95% confidence interval, 1.11-2.52; p = 0.018). Furthermore, generalized anxiety disorder was specifically higher in HCV-infected patients than those with NAFLD. Conclusion: Patients with HCV infection are at high risk of developing NPMD with or without IFN-based therapy.

KW - Antiviral therapy

KW - Chronic hepatitis C

KW - Nonalcoholic fatty liver disease

KW - Nonpsychotic mental disorders

KW - Population-based study

UR - http://www.scopus.com/inward/record.url?scp=84940452862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940452862&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2013.08.011

DO - 10.1016/j.jfma.2013.08.011

M3 - Article

C2 - 24090634

AN - SCOPUS:84940452862

VL - 114

SP - 829

EP - 834

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 9

ER -